<p>In the upper panel we compare the median CD4<sup>+</sup> cell counts of 250 virtual patients with the data of real patients from the continuous treatment arm of Dybul's clinical trial. In the lower panel we compare the median CD4<sup>+</sup> cell counts of 250 virtual patients with the data of real patients from the STI arm of Dybul's clinical trial.</p
Objective: To evaluate the correlation of total lymphocyte count (TLC) and CD4 cell count and the su...
<p>Magnitude of follow-up CD4 cell count by demographic and baseline treatment variables among patie...
BackgroundCD4 cell counts is widely used as a biomarker for treatment progression when studying the ...
<p>Comparison of the <i>in silico</i> experiments (continuous lines) with clinical data of the PRIMO...
<p>Median CD4 cell counts (cells/mm<sup>3</sup>) from baseline at down-referral to 48 months in the ...
<p>Modeled mean pVL (A) and CD4 cell count (B) over time after randomization/TI in the no treatment ...
<p>Estimated CD4 cell count dynamics in viremic patients (VIRs: n = 478) and elite controllers (ECs:...
<p>In the patient shown, we actually observed 11 CD4+ cell counts over the two years (grey line). We...
<p>Models also control for site, age, gender, and ART regimen (AZT-containing and/or NVP-containing)...
<p>The group level CD4 cell count as measured by median CD4 cell count at a particular follow-up tim...
<p>The upper limit of CD4 ( cells/mL) was truncated to cells/mL (omitting 19 outliers) to emphasize...
<p>Final total CD4+T cell counts in PB (cells/ µL) 10 years after commencement of therapy when thera...
<p>(A) Cross-validated estimates of FPRs. The bars represent the number of observed post-baseline ob...
<p>Median final total CD4+T cell counts in PB (cells/ µL) 10 years after commencement of therapy whe...
<p>In MSM from W-Europe/N-America with a proven or likely subtype B infection: a) first CD4 cell cou...
Objective: To evaluate the correlation of total lymphocyte count (TLC) and CD4 cell count and the su...
<p>Magnitude of follow-up CD4 cell count by demographic and baseline treatment variables among patie...
BackgroundCD4 cell counts is widely used as a biomarker for treatment progression when studying the ...
<p>Comparison of the <i>in silico</i> experiments (continuous lines) with clinical data of the PRIMO...
<p>Median CD4 cell counts (cells/mm<sup>3</sup>) from baseline at down-referral to 48 months in the ...
<p>Modeled mean pVL (A) and CD4 cell count (B) over time after randomization/TI in the no treatment ...
<p>Estimated CD4 cell count dynamics in viremic patients (VIRs: n = 478) and elite controllers (ECs:...
<p>In the patient shown, we actually observed 11 CD4+ cell counts over the two years (grey line). We...
<p>Models also control for site, age, gender, and ART regimen (AZT-containing and/or NVP-containing)...
<p>The group level CD4 cell count as measured by median CD4 cell count at a particular follow-up tim...
<p>The upper limit of CD4 ( cells/mL) was truncated to cells/mL (omitting 19 outliers) to emphasize...
<p>Final total CD4+T cell counts in PB (cells/ µL) 10 years after commencement of therapy when thera...
<p>(A) Cross-validated estimates of FPRs. The bars represent the number of observed post-baseline ob...
<p>Median final total CD4+T cell counts in PB (cells/ µL) 10 years after commencement of therapy whe...
<p>In MSM from W-Europe/N-America with a proven or likely subtype B infection: a) first CD4 cell cou...
Objective: To evaluate the correlation of total lymphocyte count (TLC) and CD4 cell count and the su...
<p>Magnitude of follow-up CD4 cell count by demographic and baseline treatment variables among patie...
BackgroundCD4 cell counts is widely used as a biomarker for treatment progression when studying the ...